Lamers, Christina http://orcid.org/0000-0003-0962-8171
Xue, Xiaoguang
Smieško, Martin http://orcid.org/0000-0003-2758-2680
van Son, Henri http://orcid.org/0000-0001-6206-2061
Wagner, Bea
Berger, Nadja http://orcid.org/0000-0002-4435-8317
Sfyroera, Georgia
Gros, Piet http://orcid.org/0000-0002-7782-2585
Lambris, John D.
Ricklin, Daniel http://orcid.org/0000-0001-6140-0233
Article History
Received: 3 May 2021
Accepted: 17 August 2022
First Online: 20 September 2022
Competing interests
: J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for therapeutic purposes, is the inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes (patent WO/2013/036778 relevant to this study), some of which are being developed by Amyndas Pharmaceuticals, is the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (Cp05/POT-4/APL-1 and PEGylated derivatives such as APL-2/pegcetacoplan and APL-9), and has provided paid consulting services to Achillion, Ra Pharma, Viropharma, Sanofi, Shire, LipimetiX and Baxter. D.R. is the inventor of patents or patent applications that describe complement inhibitors for therapeutic purposes (patent WO/2013/036778 relevant to this study) some of which are developed by Amyndas Pharmaceuticals, has provided paid consulting services to Roche Pharma, Sobi and Greenovation, and provided scientific lectures sponsored by Roche and Alexion. The other authors claim no conflict of interest.